Extended IGF-1
Long-acting IGF-1 for muscle growth and recovery.
IGF-1 LR3 is a long-acting variant of insulin-like growth factor with enhanced stability and bioavailability. Engineered with a 13-amino acid extension, it delivers sustained anabolic signaling for muscle growth, recovery, and metabolic optimization beyond what natural IGF-1 can achieve.
20-30hr
Half-Life
83
Amino Acids
3X
More Potent
22+
BHRC Locations
Available Option
A synthetic analog of insulin-like growth factor engineered for extended half-life and enhanced anabolic activity through direct IGF-1 receptor activation.
IGF-1 LR3 1mg per vial
Ideal For
Athletes and patients seeking accelerated muscle growth, enhanced recovery, improved body composition, and sustained anabolic signaling with fewer administrations.
The Science
IGF-1 LR3 (Long R3 Insulin-Like Growth Factor-1) is a synthetic analog of human IGF-1, modified with a 13-amino acid N-terminal extension that dramatically extends its half-life from minutes to 20-30 hours. This structural modification also reduces its binding affinity to IGF binding proteins, allowing it to remain bioactive in circulation significantly longer than endogenous IGF-1.
By binding directly to IGF-1 receptors on muscle cells, IGF-1 LR3 activates downstream anabolic pathways including PI3K/Akt and MAPK signaling—promoting protein synthesis, glucose uptake, cellular proliferation, and satellite cell activation. This makes it exceptionally effective for muscle growth, recovery from injury, and metabolic optimization.
Unlike growth hormone which works upstream through the GH/IGF-1 axis, IGF-1 LR3 provides direct receptor activation with sustained exposure—offering a targeted approach to anabolic enhancement. At BHRC, we leverage this peptide for patients seeking optimized body composition, athletic performance, and recovery acceleration.
Book a Consultation
How It Works
IGF-1 LR3 binds directly to IGF-1 receptors on muscle and other tissues, triggering powerful anabolic cascades that promote protein synthesis, cellular growth, and metabolic enhancement with sustained activity.
Binds to IGF-1 receptors on muscle cells with high affinity, initiating tyrosine kinase signaling that activates critical anabolic pathways for growth and recovery.
Activates the PI3K/Akt pathway which increases protein synthesis, glucose uptake, and cellular survival while inhibiting muscle protein breakdown.
Stimulates muscle satellite cells to proliferate and differentiate, supporting muscle repair, hypertrophy, and the creation of new muscle fibers for enhanced growth capacity.
Clinical Benefits
Direct IGF-1 receptor activation promotes rapid muscle protein synthesis and satellite cell proliferation, supporting significant hypertrophy and strength gains beyond natural capacity.
Stimulates cellular repair mechanisms and reduces recovery time between training sessions, allowing for higher training frequency and faster return from injury.
Promotes lean muscle mass while supporting fat oxidation through enhanced metabolic activity, improving muscle-to-fat ratio and overall physique aesthetics.
Increases glucose uptake in muscle tissue and enhances insulin sensitivity, supporting improved nutrient partitioning and metabolic health markers.
The 20-30 hour half-life means sustained anabolic signaling with fewer administrations compared to regular IGF-1, providing convenience and consistent results.
Lower affinity for IGF binding proteins means more free, bioactive IGF-1 LR3 in circulation—maximizing receptor engagement and anabolic effects.
Your Journey
Our medical team guides you through every step—from initial consultation to ongoing optimization.
Meet with our physician to assess your goals, health status, and determine if IGF-1 LR3 therapy is appropriate for your needs.
Comprehensive testing including IGF-1, glucose, insulin, metabolic panel, and hormone levels to establish baseline health markers.
Personalized treatment plan with precise dosing, injection training, cycle duration, and lifestyle recommendations to maximize muscle growth and recovery.
Regular follow-ups with progress tracking, lab monitoring, and protocol adjustments to ensure safe, effective anabolic results.
Safety & Candidacy
IGF-1 LR3 is a well-researched peptide analog with documented anabolic effects in preclinical and research settings. While not FDA-approved for performance enhancement, it’s used in supervised medical protocols for body composition optimization and recovery support.
4-6wks
Typical cycle duration with proper medical monitoring and planned rest periods
1x/day
Once-daily subcutaneous injection due to extended half-life
Questions
IGF-1 LR3 features a 13-amino acid N-terminal extension that extends its half-life from minutes to 20-30 hours and reduces binding to IGF binding proteins. This means it stays bioactive in your system much longer, provides more sustained anabolic signaling, and requires less frequent administration compared to regular IGF-1.
IGF-1 LR3 is administered via subcutaneous injection, typically once daily due to its extended half-life. Our clinical team provides comprehensive training on proper reconstitution, injection technique, site rotation, and storage. Some protocols may use post-workout timing to maximize nutrient partitioning to muscle tissue.
Users typically report accelerated muscle growth, enhanced recovery between training sessions, improved muscle fullness and vascularity, better nutrient partitioning, and noticeable body composition changes within 2-4 weeks. Results are maximized when combined with proper training, nutrition, and adequate protein intake. Individual responses vary based on training status, diet, and genetics.
Typical cycles range from 4-6 weeks under medical supervision, followed by an off period to maintain receptor sensitivity. Longer continuous use may lead to receptor downregulation and diminished returns. Your physician will design a protocol based on your goals, response, and monitoring data including glucose metabolism and IGF-1 levels.
Potential side effects include hypoglycemia (low blood sugar), joint discomfort, water retention, and jaw/facial changes with prolonged use. Some users experience increased appetite or insulin sensitivity changes. Blood glucose monitoring is important, especially for those with diabetes or insulin resistance. All use should be under physician supervision with regular lab monitoring.
Ideal candidates are adults seeking accelerated muscle growth, enhanced recovery, or body composition optimization who have plateaued with conventional training and nutrition. Contraindications include active malignancy, uncontrolled diabetes, pregnancy, or history of certain cancers. A physician consultation with comprehensive lab work is required to assess candidacy.
Monitoring includes regular glucose testing, IGF-1 levels, metabolic panels, insulin sensitivity markers, and clinical assessments. Body composition tracking via DEXA or other methods quantifies muscle gain and fat loss. Your physician schedules follow-ups every 2-4 weeks during active cycles to ensure safety and optimize results.
Get Started
Schedule a consultation with our medical team to learn if IGF-1 LR3 peptide therapy is right for your muscle growth and performance goals.
"*" indicates required fields
Or call us directly: +1 213-325-3373
*These statements have not been evaluated by the Food and Drug Administration. IGF-1 LR3 is not FDA-approved for performance enhancement or body composition optimization. Use is off-label and administered under medical supervision for research and therapeutic purposes. Results vary by individual based on genetics, training, nutrition, and adherence. IGF-1 LR3 may affect glucose metabolism and insulin sensitivity. Contraindicated in patients with active malignancy, uncontrolled diabetes, or certain medical conditions. A consultation with our medical team and comprehensive laboratory testing are required to determine if this therapy is appropriate for you. This product is intended for use only under qualified medical supervision.
IGF-1 LR3 is a long-acting analogue of insulin-like growth factor 1. It is one of the more potent compounds discussed in the peptide space and, correspondingly, one of the least appropriate for casual or self-directed use. Most people researching it online are not good candidates for it, and a responsible consultation frequently ends in a different recommendation.
We would rather lose the sale than dispense a growth factor to someone who has not been screened, has not had baseline glucose testing, and cannot recognise a hypoglycaemic episode. Specific dosing, reconstitution and cycle length are set by your provider at consultation rather than published as a general protocol, because the right numbers depend on your labs, goals and what else you are taking.
Book a IGF-1 LR3 ConsultationResponse varies between individuals, and the timeline below reflects what patients on a supervised protocol commonly report rather than a guaranteed outcome. Your provider will set expectations specific to your labs, history and goals.
| Timeframe | What patients typically report |
|---|---|
| Before starting | Screening and baseline labs. If screening raises anything, the protocol does not begin — this is the most important stage. |
| Week 1 | Introduction at a conservative dose with close attention to glycaemic symptoms. Any hypoglycaemic episode is reported immediately, not at the next appointment. |
| Weeks 2–4 | Patients commonly report changes in recovery and training capacity. Response varies substantially between individuals and depends heavily on training and nutrition. |
| Weeks 4–6 | Scheduled follow-up labs. Glycaemic markers are reviewed alongside IGF-1 levels. |
| End of course | Courses are deliberately short and finite. Continuation is not automatic and requires the follow-up labs to support it. |
Most patients enquiring about IGF-1 LR3 have goals that another approach addresses with a considerably better risk profile. This comparison is here to make that conversation easier, not harder.
| Option | Primary use | Administration | Best suited to |
|---|---|---|---|
| IGF-1 LR3 | Direct growth-factor activity | Subcutaneous | Narrow, carefully screened cases under close supervision |
| CJC-1295 / Ipamorelin | Stimulates the body’s own GH release | Subcutaneous, typically nightly | Most patients seeking recovery and body-composition support |
| Tesamorelin | Visceral fat reduction via the GH axis | Subcutaneous, daily | Patients with a specific visceral fat concern |
| BPC-157 / TB-500 | Tissue repair and recovery | Subcutaneous or oral | Injury recovery, without growth-factor risk |
| Testosterone or hormone optimisation | Correcting an actual measured deficiency | Varies | Patients whose labs show a genuine deficiency — frequently the real answer |
In practice, growth-hormone secretagogues address most of what patients want from IGF-1 LR3, work with the body’s own regulatory feedback, and carry meaningfully less risk. That is usually the recommendation we make.
Monitoring on this compound is a safety requirement rather than an optimisation exercise. The primary concern is glycaemic control, and it is not something you can assess by how you feel.
If you are unwilling to complete the scheduled laboratory work, we will not continue the protocol. That is not a negotiating position — unmonitored growth-factor use is genuinely unsafe.
It carries meaningfully more risk than most peptides discussed alongside it. The principal acute concern is hypoglycaemia, given its insulin-like activity. There are also theoretical concerns about growth-factor activity and cell proliferation, which is why any cancer history is a firm contraindication. It can be used under close supervision with proper screening and monitoring — it is not appropriate for unsupervised use under any circumstances.
That is the most common reason people enquire, and it is usually the wrong tool. Growth-hormone secretagogues such as CJC-1295 with Ipamorelin address most of the same goals, work with the body’s own feedback regulation, and carry considerably less risk. If your labs show an underlying hormone deficiency, correcting that is frequently the real answer. Your provider will discuss which applies to you.
Yes, and it is dispensed only after full screening, baseline labs and hypoglycaemia education. BHRC does not supply it as an unsupervised product. Material sold online under ‘research use only’ labelling is unverified for purity and dose, which is a serious problem for a compound with these risks.
Shakiness, sweating, confusion, palpitations, unusual hunger, dizziness or difficulty concentrating. These require immediate action — consuming fast-acting carbohydrate — and prompt contact with your provider. Severe hypoglycaemia is a medical emergency. You will be taught this in detail before anything is dispensed.
Yes. IGF-1 analogues are prohibited under WADA and USADA and are detectable. If you compete in any tested sport, this compound is not an option for you.
No. IGF-1 LR3 is not an FDA-approved drug. Mecasermin, a related IGF-1 product, is approved for specific rare paediatric growth conditions, which is a very different clinical context from how IGF-1 LR3 is discussed in performance settings.
A significant family history is a contraindication and we would not proceed. Given the growth-factor mechanism, this is one of the areas where we take a deliberately conservative position. There are lower-risk alternatives that address most of the same goals, and we would direct you to those.
Cost depends on the protocol and the required laboratory work, and is reviewed transparently at consultation. It is worth saying plainly: for most enquiries, the consultation concludes that a different approach is more appropriate, and no protocol is dispensed.
LR3 is a modified analogue with a substantially longer half-life, achieved by reducing binding to the proteins that normally regulate IGF-1 activity. That extended activity is precisely why it requires closer monitoring than the native peptide — the effect persists longer, and so does the hypoglycaemia risk.
BHRC offers physician-supervised consultations across its locations, including West Hollywood, West Los Angeles, Valencia, Paradise Valley and Summerlin. A consultation determines whether IGF-1 LR3 is appropriate at all — and frequently the outcome is a recommendation for something else.
Most patients researching IGF-1 LR3 are better served by one of the options below. These are the pages we most often direct people to instead.
The literature below is peer-reviewed background on IGF-1 LR3 and the mechanisms discussed on this page. It is provided so you can read the primary sources yourself. It is not evidence of any particular outcome at BHRC, and much of it is preclinical — animal or cell-culture work that has not been replicated in humans. Your provider will discuss what the evidence does and does not support for your situation.
